Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

SanBio Company Limited

SNBIFPNK
Healthcare
Biotechnology
$16.45
$0.00(0.00%)
U.S. Market opens in 8h 15m

SanBio Company Limited Fundamental Analysis

SanBio Company Limited (SNBIF) shows weak financial fundamentals with a PE ratio of -53.81, profit margin of 0.00%, and ROE of -2.53%. The company generates N/A in annual revenue with weak year-over-year growth of 0.00%.

Key Strengths

Cash Position161.03%
PEG Ratio-0.07
Current Ratio5.28

Areas of Concern

ROE-2.53%
Operating Margin0.00%
We analyze SNBIF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -243.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-243.0/100

We analyze SNBIF's fundamental strength across five key dimensions:

Efficiency Score

Weak

SNBIF struggles to generate sufficient returns from assets.

ROA > 10%
-1.43%

Valuation Score

Excellent

SNBIF trades at attractive valuation levels.

PE < 25
-53.81
PEG Ratio < 2
-0.07

Growth Score

Moderate

SNBIF shows steady but slowing expansion.

Revenue Growth > 5%
0.00%
EPS Growth > 10%
57.83%

Financial Health Score

Moderate

SNBIF shows balanced financial health with some risks.

Debt/Equity < 1
2.64
Current Ratio > 1
5.28

Profitability Score

Weak

SNBIF struggles to sustain strong margins.

ROE > 15%
-253.03%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is SNBIF Expensive or Cheap?

P/E Ratio

SNBIF trades at -53.81 times earnings. This suggests potential undervaluation.

-53.81

PEG Ratio

When adjusting for growth, SNBIF's PEG of -0.07 indicates potential undervaluation.

-0.07

Price to Book

The market values SanBio Company Limited at 376.13 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

376.13

EV/EBITDA

Enterprise value stands at -56.21 times EBITDA. This is generally considered low.

-56.21

How Well Does SNBIF Make Money?

Net Profit Margin

For every $100 in sales, SanBio Company Limited keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $-2.53 in profit for every $100 of shareholder equity.

-2.53%

ROA

SanBio Company Limited generates $-1.43 in profit for every $100 in assets, demonstrating efficient asset deployment.

-1.43%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $0.00 in free cash annually.

$0.00

FCF Yield

SNBIF converts 0.00% of its market value into free cash.

0.00%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-53.81

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.07

vs 25 benchmark

P/B Ratio

Price to book value ratio

376.13

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

2.64

vs 25 benchmark

Current Ratio

Current assets to current liabilities

5.28

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-2.53

vs 25 benchmark

ROA

Return on assets percentage

-1.43

vs 25 benchmark

ROCE

Return on capital employed

-1.88

vs 25 benchmark

How SNBIF Stacks Against Its Sector Peers

MetricSNBIF ValueSector AveragePerformance
P/E Ratio-53.8129.45 Better (Cheaper)
ROE-253.03%779.00% Weak
Net Margin0.00%-24936.00% (disorted) Weak
Debt/Equity2.640.26 Weak (High Leverage)
Current Ratio5.284.65 Strong Liquidity
ROA-143.01%-19344.00% (disorted) Weak

SNBIF outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews SanBio Company Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-100.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

32.73%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

10.53%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ